Patents by Inventor Antonius Jozef Maria Berns

Antonius Jozef Maria Berns has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220023293
    Abstract: The invention relates to a combination of a FGFR inhibitor and an EZH2 inhibitor for use in a method of treating a patient suffering from a BRCA1-associated protein 1 (BAP1) negative cancer. The invention further relates to a pharmaceutical preparation, comprising a FGFR inhibitor and an EZH2 inhibitor, to the use of said pharmaceutical preparation in a method of treating BAP1-negative cancer, to methods of identifying a patient with cancer, who is eligible for treatment with a combination of a FGFR inhibitor and an EZH2 inhibitor, and to a mouse model for mesothelioma.
    Type: Application
    Filed: December 3, 2019
    Publication date: January 27, 2022
    Inventors: Antonius Jozef Maria BERNS, Jitendra BADHAI, Maarten Matthijs Sharif VAN LOHUIZEN
  • Publication number: 20040033974
    Abstract: The invention relates to the use of inhibitors of the expressed proteins of the murine genes and/or their human homologues listed in Table 1 for the preparation of a therapeutical composition for the treatment of cancer, in particular for the treatment of solid tumors of lung, colon, breast, prostate, ovarian, pancreas and leukemia. The invention also relates to the therapeutical compositions comprising the inhibitors and to methods for development of the inhibitor compounds.
    Type: Application
    Filed: August 19, 2002
    Publication date: February 19, 2004
    Applicant: Kylix B.V.
    Inventors: Anders Henrik Lund, Antonius Jozef Maria Berns, Maarten Matthijs Sharif Van Lohuizen, Carla Pedro Martins, Henricus Martinus Maria Mikkers, Jack Richard Lenz
  • Patent number: 6384298
    Abstract: Transgenic mice having a phenotype characterized by the substantial depletion of a mature lymphocytic cell type otherwise naturally occurring in the species from which the transgenic mouse is derived. The phenotype is conferred in the transgenic mouse by a transgene contained in at least the precursor stem cell of the lymphocytic cell type which is depleted. The transgene comprises a DNA sequence encoding a lymphatic polypeptide variant which inhibits maturation of the lymphocytic cell type.
    Type: Grant
    Filed: July 24, 1997
    Date of Patent: May 7, 2002
    Assignee: Genpharm International
    Inventors: Paulus Jacobus Angelinus Krimpenfort, Antonius Jozef Maria Berns
  • Patent number: 5695765
    Abstract: The invention relates to a pseudorabies virus (PRV) not found in nature and having a genome containing a mutation in the protein kinase gene region and/or in the 28K gene region. The mutation is e.g. a nucleic acid substitution, deletion, insertion or inversion, or a combination thereof. The mutations are introduced, by genetic engineering techniques, into the genome of a naturally occuring PRV, preferably NIA-3. Insertions may be nucleic acid sequences encoding antigenic polypeptides characteristic of a pathogen found in pigs. The invention also relates to vaccines containing a pseudorabies virus according to the invention, and to a process for preparing such vaccines.
    Type: Grant
    Filed: January 25, 1995
    Date of Patent: December 9, 1997
    Assignee: Stichting Voor de Technische Wetenschappen
    Inventors: Niels De Wind, Maria Madalene Van Zijl, Arnold Leonard Jozef Gielkens, Antonius Jozef Maria Berns